Seth Klarman
Baupost Group
Seth Klarman Paratek Pharmaceuticals Inc stake
total: 272
Baupost Group PRTK trades
- Total transactions:
- 5
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 1
- Held since:
- 2014 Q4
- Held for:
- 20 quarters
- Latest activity:
- 2019 Q4
According to 2026 Q2 report, Seth Klarman doesn't hold any Paratek Pharmaceuticals Inc (PRTK) shares. To date, the estimated cost basis is nearly $29.97 for "buy" trades and estimated average "sell" price is $5.9. Baupost Group first purchased PRTK in 2014 Q4, initially acquiring about 1.74M shares. Since the initial investment in Paratek Pharmaceuticals Inc (PRTK), Baupost Group has made 4 more transactions.
When did Seth Klarman sell Paratek Pharmaceuticals Inc (PRTK)?
Seth Klarman sold off the entire Paratek Pharmaceuticals Inc (PRTK) position in 2019 Q4.
When did Seth Klarman buy Paratek Pharmaceuticals Inc (PRTK)?
Seth Klarman first invested in Paratek Pharmaceuticals Inc (PRTK) in 2014 Q4 at the reported quarter-end price of $35.79 per share.
What's the cost basis of Baupost Group's PRTK stake?
The estimated cost basis for Paratek Pharmaceuticals Inc (PRTK) stake is around $29.97 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $29.97
- Weighted AVG sell price:
- $5.90
Seth Klarman's historical trades in Paratek Pharmaceuticals Inc
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2019 Q4
|
0.00%
|
$4.32
|
-100% (-2,394,498)
|
|||
|
2017 Q2
|
0.66%
|
$24.10
|
+17.12% (+350,000)
|
|||
|
2016 Q2
|
0.39%
|
$13.91
|
+32.37% (+500,000)
|
|||
|
2015 Q2
|
0.66%
|
$25.77
|
-10.99% (-190,720)
|
|||
|
2014 Q4
|
1.22%
|
$35.79
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.